Llwytho...
Genetic markers predict primary non-response and durable response to anti-TNF biologic therapies in Crohn’s disease
BACKGROUND: One-fifth of patients with Crohn’s Disease (CD) are primary non-responders (PNR) to anti-tumor necrosis factor (anti-TNF) therapy, and an estimated 10–15% will fail therapy annually. Little is known about the genetics of response to anti-TNF therapy. The aim of our study was to identify...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Am J Gastroenterol |
|---|---|
| Prif Awduron: | , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
2016
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5143156/ https://ncbi.nlm.nih.gov/pubmed/27596696 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ajg.2016.408 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|